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Letrozole: 10 years and getting better
Over the past decade, clinical trials have shown that aro-
matase inhibitors (AIs), as a class, are superior to
tamoxifen in advanced and early hormone receptor-posi-
tive breast cancer. As a result of these trials, AIs have been
approved in a variety of settings and are quickly replacing
tamoxifen as standard adjuvant therapy for postmenopausal
women with hormone-sensitive tumors. Of the three AIs
currently approved, letrozole is the most potent inhibitor of
aromatase activity and of tumor proliferation. This year
marks the 10th anniversary of Novartis bringing letrozole
to the market. Since then, letrozole has become one of a
range of indispensable medications available to physicians
for the treatment of early and advanced breast cancer.
This supplement will review the development of
letrozole and its efﬁcacy in several breast cancer treatment
settings, as well as discuss the management of common
comorbidities associated with the use of AIs.
The supplement will begin with ‘‘reminiscences from
the early days,’’ providing an historical overview of the
letrozole development program by scientists involved in
the discovery of letrozole in the laboratory, and the clini-
cians and statisticians who devised the structure of the
trials. Modern third-generation AIs effectively block the
production of estrogen without exerting effects on other
steroidogenic pathways. Dr. Bhatnagar reviews the mech-
anism of action of letrozole, leading to greater suppression
of estrogen than other AIs, including anastrozole, exe-
mestane, formestane, and aminoglutethimide. He also
discusses the series of uniquely designed letrozole clinical
trials, which set the standard for the ﬁeld and increased
international exchange of ideas and expertise among
investigators.
In the advanced breast cancer setting, letrozole is the
only third-generation AI that has consistently demonstrated
signiﬁcant improvements in objective response rate, time to
progression, and early overall survival. As the primary
investigator of the PO25 study, I will describe the results of
this trial, highlighting the evidence for the superiority of
letrozole over tamoxifen as ﬁrst-line endocrine therapy in
postmenopausal women with advanced breast cancer.
The beneﬁts of letrozole extend into the neoadjuvant
setting as well. As neoadjuvant treatment, letrozole
reduced tumor volume and allowed women with inoperable
breast cancer or who were not candidates for breast-con-
serving surgery to undergo breast preservation procedures.
Drs. Ellis and Ma discuss how letrozole, administered in
the neoadjuvant setting, has also shown efﬁcacy in the
treatment of human epidermal growth factor receptor 2
(HER2)- and/or HER1-positive tumors.
Extended adjuvant letrozole is a new treatment para-
digm that now offers women who have completed 5 years
of tamoxifen the opportunity to further protect themselves
against relapse. Letrozole was the ﬁrst AI approved in the
extended adjuvant setting. Dr. Goss summarizes the results
from the pivotal NCIC MA.17 trial, which showed a sig-
niﬁcant reduction in recurrence risk, the risk of distant
metastases, and a survival advantage in node-positive
patients. The results from this landmark trial led to the
approval of letrozole for this indication. Dr. Goss also
discusses the results from the latest MA.17 analyses post
unblinding, which demonstrate that letrozole is effective
even in those women who have spent a prolonged period
off tamoxifen. The beneﬁt of letrozole continues with
longer duration (at least out to 4 years), and the option of
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be discussed with all patients completing adjuvant
tamoxifen.
The results from the uniquely designed Breast Interna-
tional Group (BIG) 1-98 trial have led to the approval of
letrozole as an initial adjuvant therapy. The eagerly awaited
monotherapy arm analysis of the BIG 1-98 trial was
recently presented in Istanbul at the 31st Annual European
Society for Medical Oncology congress, and will be
reviewed and compared with the primary core analysis by
Drs. Koeberle and Thuerlimann. The monotherapy results
have conﬁrmed the ﬁndings from the primary core analysis,
which showed that compared with tamoxifen, letrozole
signiﬁcantly reduced the risk of recurrence by 19% and
especially reduced the risk of distant metastases by 27%.
This is an extremely important ﬁnding, as the presence of
distant metastases is often regarded as a marker of
decreased survival, thus suggesting that the superior efﬁ-
cacy of letrozole in reducing the risk of distant metastases
might also translate into a signiﬁcant survival beneﬁt. The
beneﬁt of letrozole extends to patients at increased risk of
recurrence (i.e., node-positive and chemotherapy-treated
patients), supporting the use of letrozole as standard
adjuvant therapy for postmenopausal women with endo-
crine-responsive breast cancer.
The signiﬁcance of the superior potency of letrozole
compared to other AIs is often discussed. Dr. O’Shaugh-
nessy will provide an insightful overview of the currently
ongoing Femara versus Anastrozole Clinical Evaluation
(FACE) trial, which is comparing the efﬁcacy and safety of
letrozole versus anastrozole in over 4000 hormone recep-
tor-positive, node-positive postmenopausal patients. Node-
positive patients were selected because this population has
a higher risk of relapse, with events occurring earlier than
in node-negative patients, thereby providing an answer
more quickly than conducting a trial in a broader popula-
tion including patients with node-negative tumors. Results
of the FACE trial will provide important insights into the
optimal adjuvant treatment strategy for hormone receptor-
positive postmenopausal women with early breast cancer.
Although AIs have demonstrated superior efﬁcacy and
better overall safety compared with tamoxifen in
randomized controlled trials, they do not provide the car-
dioprotective beneﬁts associated with tamoxifen, and bone
loss may be a concern with their long-term adjuvant use.
However, the impact of these adverse events is difﬁcult to
assess because cardiovascular disease, bone loss, and
osteoporosis commonly also occur in postmenopausal
women not under treatment with AIs. Furthermore, most of
the available safety data come from trials comparing AIs
and tamoxifen, a drug with known cardioprotective and
bone-sparing effects. As discussed by Dr. Perez, patients at
a higher risk for osteoporosis can be managed using bone
mineral density monitoring, and prophylactic bisphospho-
nates to protect long-term bone health. Importantly, AIs
decrease the risks of thromboembolic and cerebrovascular
events compared with tamoxifen, and the overall rate of
cardiovascular events in patients treated with AIs is com-
parable to that recorded in placebo-treated patients and
within the range seen in age-matched, non-breast cancer
populations.
Of course, no discussion of therapy is complete with-
out considering the patient’s perspective. Thanks to the
growing literature and access to the Internet, patient
awareness of new adjuvant therapies has grown, and
patients are now, in many cases, aware of their treatment
options and what to expect in terms of efﬁcacy and
safety. Drs. Harbeck and Haidinger examine the clinical
use of letrozole from the patient’s perspective and assess
how it has improved treatment outcomes across the breast
cancer continuum, including advanced or metastatic
breast cancer, extended and initial adjuvant and neoad-
juvant therapy.
The supplement ends with a look into the future. A
review by Drs. Ellis and Ma discusses the individualized
use of letrozole treatment, tailored according to a patient’s
needs and in combination with other agents. This new
treatment paradigm will greatly improve outcomes and has
the potential to revolutionize breast cancer care.
I hope that this supplement will not only highlight the
superior efﬁcacy and safety proﬁle of letrozole but will
also further validate the use of AIs for the treatment of
postmenopausal women with hormone-sensitive breast
cancer.
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